Passos Silva Marisa, Caeiro Daniel, Fernandes Paula, Guerreiro Cláudio, Vilela Eduardo, Ponte Marta, Dias Adelaide, Alves Fernando, Morais Jorge, Mello Andreza, Santos Lino, Castelões Paula, Gama Vasco
Serviço de Cardiologia, Centro Hospitalar Vila Nova de Gaia/Espinho, Vila Nova de Gaia, Portugal.
Serviço de Cardiologia, Centro Hospitalar Vila Nova de Gaia/Espinho, Vila Nova de Gaia, Portugal.
Rev Port Cardiol. 2017 Nov;36(11):833-842. doi: 10.1016/j.repc.2017.01.003. Epub 2017 Nov 8.
Extracorporeal membrane oxygenation (ECMO) provides mechanical pulmonary and circulatory support for patients with shock refractory to conventional medical therapy. In this study we aim to describe the indications, clinical characteristics, complications and mortality associated with use of ECMO in a single tertiary hospital.
We conducted a retrospective observational cohort study of all patients supported with ECMO in two different intensive care units (general and cardiac), from the first patient cannulated in April 2011 up to October 2016.
Overall, 48 patients underwent ECMO: 29 venoarterial ECMO (VA-ECMO) and 19 venovenous ECMO (VV-ECMO). In VA-ECMO, acute myocardial infarction was the main reason for placement. The most frequent complication was lower limb ischemia and the most common organ dysfunction was acute renal failure. In VV-ECMO, acute respiratory distress syndrome after viral infection was the leading reason for device placement. Access site bleeding and hematologic dysfunction were the most prevalent complication and organ dysfunction, respectively. Almost 70% of ECMO episodes were successfully weaned in each group. Survival to discharge was 37.9% for VA-ECMO and 63.2% for VV-ECMO. In VA-ECMO, the number of inotropic agents was a predictor of mortality.
Patients with respiratory indications for ECMO experienced better survival than cardiac patients. The need for more inotropic drugs was a predictor of mortality in VA-ECMO. This is the first published record of the overall experience with ECMO in a Portuguese tertiary hospital.
体外膜肺氧合(ECMO)为传统药物治疗难以纠正休克的患者提供机械性肺和循环支持。在本研究中,我们旨在描述一家三级医院使用ECMO的适应证、临床特征、并发症及死亡率。
我们对2011年4月首例接受ECMO治疗至2016年10月期间,在两个不同重症监护病房(综合和心脏)接受ECMO支持的所有患者进行了回顾性观察队列研究。
总体而言,48例患者接受了ECMO治疗:29例采用静脉-动脉ECMO(VA-ECMO),19例采用静脉-静脉ECMO(VV-ECMO)。在VA-ECMO中,急性心肌梗死是植入的主要原因。最常见的并发症是下肢缺血,最常见的器官功能障碍是急性肾衰竭。在VV-ECMO中,病毒感染后急性呼吸窘迫综合征是植入设备的主要原因。穿刺部位出血和血液学功能障碍分别是最常见的并发症和器官功能障碍。每组中近70%的ECMO治疗过程成功撤机。VA-ECMO患者出院生存率为37.9%,VV-ECMO患者为63.2%。在VA-ECMO中,血管活性药物的使用数量是死亡率的一个预测因素。
有呼吸适应证接受ECMO治疗的患者比心脏疾病患者生存率更高。在VA-ECMO中,需要更多血管活性药物是死亡率的一个预测因素。这是葡萄牙一家三级医院关于ECMO总体经验首次发表的记录。